RAS Dialogue
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
RAS-binding compounds: approaching the undruggable from a different perspectiveSmall antibody derivatives called nanobodies have been discovered that inhibit RAS functions in living cells. Drug candidates can be developed with assays in which they compete with nanobodies for RAS binding in vitro
-
Update: Mutations in Human Cancers Through the Lens of KRASKRAS is the most commonly mutated oncogene in human cancers. Analysis of the mutations in other genes in thousands of human tumors in which KRAS is highly mutated reveals patterns that may guide research into the biology of human cancers.
-
New Clarity on the Warburg EffectCancer cells divert glucose from ATP-rich oxidative phosphorylation, to ATP-poor glycolysis, which produces lactic acid as a byproduct. New research is revealing the mechanisms regulating the balance between oxidation and glycolysis.
-
Deploying a RAS pipeline against the SARS-CoV-2 pandemicThe NCI RAS Initiative has developed a set of advanced protein expression and purification protocols. Those protocols have been applied to supply antibody and antigen reagents for several SARS-CoV-2 / Covid-19 pandemic research projects.
-
SOS signaling in RAS-mutated cancersSOS proteins participate in controlling the activity of the RAS pathway, even when RAS itself is mutated and driving cancer. Inhibitors of SOS in combination with other drugs show promise as elements of new cancer therapies.